Enter your search term above.

Funding opportunities

In keeping with our mission, the LCRF grant program provides funding for research into the prevention, diagnosis, treatment and cure of lung cancer. Our funding mechanisms are designed to fund innovative projects across a variety of diverse topics and to support the careers of talented scientists. To learn about research that has been previously funded by LCRF, please visit the Our Investigators section. Information for investigators seeking funding for research, including an overview of our funding mechanisms and any current requests for proposals, can be found below. For questions about our grants, please contact us at grants@LCRF.org.

Applications for the 2021 grant cycle are now closed.

About Our Grants

LCRF-AstraZeneca Grant Program

New treatment modalities such as targeted therapies and immune therapies pose new and unique challenges. To help address the most profound of these challenges, the LCRF-AstraZeneca grant program aims to fund innovative projects to:

  • Understand primary and acquired resistance to osimertinib and novel combinations targeting concurrent driver mutations
  • Develop more effective approaches to address disease progression in patients treated with durvalumab
  • Discover novel biomarkers for predicting response to osimertinib or durvalumab and to identify patients who are at higher risk of recurrence (translational research preferred)
  • Identify predictive biomarkers, understand the underlying biology and develop novel interventions for immune mediated adverse events, such as pneumonitis, in patients receiving durvalumab

These awards provide a maximum of $150,000 in funding over a period of two years to early- and mid-career investigators. Proposals which specifically focus on either osimertinib or durvalumab will be strongly favored. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.

Applications will be submitted through a two-step process consisting of a Letter of Intent (LOI) and full proposal. Applicants whose LOI submission is reviewed favorably will be invited to complete a full proposal. Letters of Intent will be accepted through April 30, 2021.

LCRF Pilot Grant Program

The LCRF pilot grant program funds innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, and other research focused on one or more of the following topics:

  • Lung cancer biology
  • Prevention and screening for early detection
  • Identification of new biomarkers
  • Development of more effective and less toxic therapies including but not limited to targeted and immune-therapies
  • Mechanisms of sensitivity and resistance to lung cancer therapies
  • Supportive measures for people with lung cancer and their families
  • Quality of care and outcomes research

These awards provide a maximum of $150,000 in funding over a period of two years to early- and mid-career investigators. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.

Applications will be submitted through a two-step process consisting of a Letter of Intent (LOI) and full proposal. Applicants whose LOI submission is reviewed favorably will be invited to complete a full proposal. Letters of Intent will be accepted through April 30, 2021.

LCRF Research Grant on Disparities in Lung Cancer

While scientific advances steadily continue to reduce lung cancer incidence and deaths, the disease disproportionately affects various groups such as African Americans, Native Americans, low socioeconomic status populations and people from certain geographic locations. Despite progress to reduce the burden of tobacco, disparities in tobacco-related morbidity and mortality remain, and inequitable receipt of evidence-based lung cancer care continues to compound these disparities. We encourage applications on a wide variety of disparities-related topics including but not limited to the following:

  • Gender disparities in lung cancer burden
  • Causes and risk factors for lung cancer among never smokers
  • Influence of social and biological risk factors on lung cancer outcomes, access to and use of care, and quality of care
  • Genetic and gene-environment interactions
  • Interactions and contributions of multiple factors (e.g. smoking, genetics, environment, societal factors) to disparities in lung cancer outcomes
  • Contribution of healthcare access and quality to disparities in outcomes
  • Disparities related to other factors such as geography, socioeconomic status, and age

These awards provide a maximum of $150,000 in funding over a period of two years to early- and mid-career investigators. For complete details, eligibility criteria, and application instructions, please refer to the request for proposals.

The LCRF Research Grant on Disparities in Lung Cancer RFP applications will be accepted through May 7, 2021.

Mailing List

To receive RFP announcements and other updates related to LCRF funding opportunities, you may subscribe to our mailing list using the form below. You may opt out of these communications at any time.

Name 
Email
Institution